154 related articles for article (PubMed ID: 8880901)
1. Structural characterization of the tumor suppressor p16, an ankyrin-like repeat protein.
Boice JA; Fairman R
Protein Sci; 1996 Sep; 5(9):1776-84. PubMed ID: 8880901
[TBL] [Abstract][Full Text] [Related]
2. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
Baumgartner R; Fernandez-Catalan C; Winoto A; Huber R; Engh RA; Holak TA
Structure; 1998 Oct; 6(10):1279-90. PubMed ID: 9782052
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressor p16INK4A: structural characterization of wild-type and mutant proteins by NMR and circular dichroism.
Tevelev A; Byeon IJ; Selby T; Ericson K; Kim HJ; Kraynov V; Tsai MD
Biochemistry; 1996 Jul; 35(29):9475-87. PubMed ID: 8755727
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A.
Li J; Byeon IJ; Ericson K; Poi MJ; O'Maille P; Selby T; Tsai MD
Biochemistry; 1999 Mar; 38(10):2930-40. PubMed ID: 10074345
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4.
Li J; Poi MJ; Qin D; Selby TL; Byeon IJ; Tsai MD
Biochemistry; 2000 Feb; 39(4):649-57. PubMed ID: 10651629
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).
Yuan C; Li J; Selby TL; Byeon IJ; Tsai MD
J Mol Biol; 1999 Nov; 294(1):201-11. PubMed ID: 10556039
[TBL] [Abstract][Full Text] [Related]
8. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
Li J; Joo SH; Tsai MD
Biochemistry; 2003 Nov; 42(46):13476-83. PubMed ID: 14621993
[TBL] [Abstract][Full Text] [Related]
9. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
Yarbrough WG; Buckmire RA; Bessho M; Liu ET
J Natl Cancer Inst; 1999 Sep; 91(18):1569-74. PubMed ID: 10491434
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the CDK4/6 inhibitory protein p18INK4c provides insights into ankyrin-like repeat structure/function and tumor-derived p16INK4 mutations.
Venkataramani R; Swaminathan K; Marmorstein R
Nat Struct Biol; 1998 Jan; 5(1):74-81. PubMed ID: 9437433
[TBL] [Abstract][Full Text] [Related]
11. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
12. Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6.
Noh SJ; Li Y; Xiong Y; Guan KL
Cancer Res; 1999 Feb; 59(3):558-64. PubMed ID: 9973200
[TBL] [Abstract][Full Text] [Related]
13. Structure of the cyclin-dependent kinase inhibitor p19Ink4d.
Luh FY; Archer SJ; Domaille PJ; Smith BO; Owen D; Brotherton DH; Raine AR; Xu X; Brizuela L; Brenner SL; Laue ED
Nature; 1997 Oct; 389(6654):999-1003. PubMed ID: 9353127
[TBL] [Abstract][Full Text] [Related]
14. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.
Guan KL; Jenkins CW; Li Y; Nichols MA; Wu X; O'Keefe CL; Matera AG; Xiong Y
Genes Dev; 1994 Dec; 8(24):2939-52. PubMed ID: 8001816
[TBL] [Abstract][Full Text] [Related]
15. The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner.
Li J; Melvin WS; Tsai MD; Muscarella P
Biochemistry; 2004 Apr; 43(14):4394-9. PubMed ID: 15065884
[TBL] [Abstract][Full Text] [Related]
16. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
Villacañas O; Pérez JJ; Rubio-Martínez J
J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
[TBL] [Abstract][Full Text] [Related]
17. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4.
Chan FK; Zhang J; Cheng L; Shapiro DN; Winoto A
Mol Cell Biol; 1995 May; 15(5):2682-8. PubMed ID: 7739548
[TBL] [Abstract][Full Text] [Related]
18. NMR structural characterization of the CDK inhibitor p19INK4d.
Kalus W; Baumgartner R; Renner C; Noegel A; Chan FK; Winoto A; Holak TA
FEBS Lett; 1997 Jan; 401(2-3):127-32. PubMed ID: 9013872
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
[TBL] [Abstract][Full Text] [Related]
20. Direct binding of the N-terminus of HTLV-1 tax oncoprotein to cyclin-dependent kinase 4 is a dominant path to stimulate the kinase activity.
Li J; Li H; Tsai MD
Biochemistry; 2003 Jun; 42(22):6921-8. PubMed ID: 12779347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
